Clinical Trials
12
Active:2
Completed:2
Trial Phases
3 Phases
Phase 1:6
Phase 2:4
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (50.0%)Phase 2
4 (33.3%)Phase 3
2 (16.7%)Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
Phase 1
Not yet recruiting
- Conditions
- Polycythemia Vera
- Interventions
- Drug: BEBT-507 Injection
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- BeBetter Med Inc
- Target Recruit Count
- 90
- Registration Number
- NCT07012109
- Locations
- 🇨🇳
Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
Phase 3
Recruiting
- Conditions
- HR+/HER2- Locally Advanced, Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- BeBetter Med Inc
- Target Recruit Count
- 330
- Registration Number
- NCT06998108
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 3
Recruiting
- Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Drug: Ifupinostat Hydrochloride for Injection
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- BeBetter Med Inc
- Target Recruit Count
- 416
- Registration Number
- NCT06792253
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Non-Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
- Interventions
- Drug: BEBT-109 Capsule
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- BeBetter Med Inc
- Target Recruit Count
- 200
- Registration Number
- NCT06706713
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Advanced Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- BeBetter Med Inc
- Target Recruit Count
- 120
- Registration Number
- NCT06685796
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
- Prev
- 1
- 2
- 3
- Next
News
No news found